CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) for Potential Breaches of Fiduciary Duties

Business Wire 21-Nov-2018 4:35 PM

Zamansky LLC announces that it is investigating Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:ALNY) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of Alnylam who still holds your shares, please contact our firm for information.

It has recently emerged from public reports that Alnylam appears to have overstated the safety and effectiveness of its new drug Onpattro. This investigation concerns Alnylam's possible misleading public statements that underplayed health risks to patients and have exposed the Company to significant liability. According to Jake Zamansky, investment fraud attorney, among the fiduciary duties owed by Alnylam's officers and directors to the Company and its shareholders is the obligation to avoid such potentially dangerous conduct.

What Alnylam Shareholders Can Do

If you are a current shareholder of Alnylam who still holds your stock, please contact us to review or discuss your legal rights. You may, without obligation or cost to you, email jake@zamansky.com or call the law firm at (212) 742-1414.

About Zamansky LLC

Zamansky LLC is a leading investment fraud law firm with experience handling securities, hedge fund, ERISA and other shareholder class action and derivative litigation. We are investment fraud attorneys who represent both individual and institutional investors. Our practice is nationally recognized for our ability to aggressively prosecute cases and recover investment losses.

To learn more about Zamansky LLC, please visit our website, http://www.zamansky.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005538/en/